Hisamitsu Pharmaceutical CoFSE:4530 89 ROC (Joel Greenblatt) % is 27.27% as of Nov. 2025, which is 14% below its 10-year median of 31.59. GuruFocus rates FSE:4530 with a GF Score™ of 89/100 and a GF Value™ of 円3,237.07. Among 978 Drug Manufacturers companies, Hisamitsu Pharmaceutical Co ranks better than 70.35% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Hisamitsu Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2025 was 27.27%.
The historical rank and industry rank for Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) % or its related term are showing as below:
FSE:4530'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 17.86 Med: 31.59 Max: 44.45
Current: 25.4
During the past 13 years, Hisamitsu Pharmaceutical Co's highest ROC (Joel Greenblatt) % was 44.45%. The lowest was 17.86%. And the median was 31.59%.
FSE:4530's ROC (Joel Greenblatt) % is ranked better than 70.35% of 978
companies
in the Drug Manufacturers industry
Industry Median: 11.45
vs FSE:4530: 25.40
Hisamitsu Pharmaceutical Co (FSE:4530) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co ROC (Joel Greenblatt) % Chart
FSE:4530 vs ESPR, AMPH, ETON: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) % falls into.
Hisamitsu Pharmaceutical Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Nov. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 27.27% mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a ROC (Joel Greenblatt) % of 27.27% as of Nov. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Hisamitsu Pharmaceutical Co and its competitors. This is 14% below median its historical median of 31.59. Over the past decade, Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) % has ranged from 17.86 to 44.45. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #290 out of 978 companies in the Drug Manufacturers industry, placing it in the top 29.7%.
Is Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) % too high?
Hisamitsu Pharmaceutical Co's current ROC (Joel Greenblatt) % of 27.27% is 14% below median its 10-year median of 31.59. Over the past 10 years, this metric has ranged from a low of 17.86 to a high of 44.45. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.45. Hisamitsu Pharmaceutical Co's value of 27.27% is 138.2% above this industry median. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #290 out of 978 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) % compare to ESPR and AMPH?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #290 out of 978 companies for ROC (Joel Greenblatt) %. This puts Hisamitsu Pharmaceutical Co in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.45. Hisamitsu Pharmaceutical Co's value of 27.27% is 138.2% above this benchmark. Historically, Hisamitsu Pharmaceutical Co's own ROC (Joel Greenblatt) % has ranged from 17.86 to 44.45 over the past decade. While the company's 10-year median is 31.59 vs. the industry median of 11.45, Hisamitsu Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.45, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current ROC (Joel Greenblatt) % of 27.27% is 138.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current ROC (Joel Greenblatt) % is 27.27%, which is 14% below median its own 10-year median of 31.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current ROC (Joel Greenblatt) % of 27.27%. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current ROC (Joel Greenblatt) % is 27.27%, which is 14% below median its 10-year median of 31.59 and 138.2% above the Drug Manufacturers industry median of 11.45. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current ROC (Joel Greenblatt) % is 27.27% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
ROC (Joel Greenblatt) %: 27.27% (14% below median its 10-year median of 31.59)
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 138.2% above the Drug Manufacturers median (#290 of 978)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
